The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
Zydus Pinkathon will be led by women to raise awareness on breast cancer and women's health
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Importantly, the combination of giredestrant and everolimus was well tolerated
Subscribe To Our Newsletter & Stay Updated
